February 27, 2019/Suzhou/ -- TenNor Therapeutics Limited, a clinical-stage company focused on developing differentiated infectious disease products, announced that it has received US Food and Drug Administration (FDA) Qualified Infectious Disease Product (QIDP) designation for TNP-2092 powder for injection (TNP-2092 IV), for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Catheter Related Blood Stream Infections (CRBSI) and Prosthetic Joint Infections (PJI). Benefits available under QIDP designation include priority review, fast track and 5-year extension of market exclusivity.

TNP-2092 IV is one of the leading products in TenNor’s new drug development portfolio. It is currently in Phase II clinical trials in the US. TNP-2092 is a highly differentiated product, not only active against pathogens that are resistant to available antibiotics (such as MRSA), but also active against bacteria living in biofilms. TNP-2092 IV has the potential to be used for the treatment of medical device associated bacterial biofilm infections, a major unmet medical need in infectious disease area currently requiring surgical intervention.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com